Emily Larrimer Savas

Emily Savas is an experienced litigator whose practice concentrates on intellectual property and representing and counseling generic drug manufacturers in Hatch-Waxman patent litigations. Emily is a registered patent agent and has experience negotiating sponsored research and clinical trial agreements.

Pharmaceutical Patent Litigation

Emily represents pharmaceutical clients through all stages of litigation arising under the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act. Emily's experience includes preparing Paragraph IV notice letters, invalidity and non-infringement contentions, all aspects of fact and expert discovery, claim construction proceedings, dispositive motion practice, preliminary injunction proceedings, trial, and appeal.  Emily has additional experience drafting and negotiating settlement agreements related to her litigation practice.

Emily leads patent litigations concerning infringement and invalidity of patent claims directed to pharmaceutical compounds and formulations, crystalline forms of drug substances, x-ray powder diffraction peak patterns, pharmacokinetics, and methods of treating a wide variety of diseases, including multiple sclerosis, depression, psoriasis, Parkinson's disease, chronic obstructive pulmonary disease, overactive bladder, attention deficit disorder and narcolepsy.

Contract Negotiation

Emily returned to Locke Lord in 2013 after serving as Contracts Officer at University of California, San Diego, where she provided guidance to University researchers and business officers on medical industry contracts and principal investigator-initiated clinical trial agreements. She has experience negotiating contract terms regarding intellectual property ownership, material transfers, confidentiality and publication, export control regulations, and dispute resolution.

Patent and Trademark Prosecution

Emily is a registered patent agent with an advanced degree in molecular biology, and has extensive experience in both trademark prosecution and litigation. She has represented business owners in a variety of trademark prosecutions and disputes, including ownership and infringement.

Emily is currently pro bono counsel for a non-profit organization promoting access to essential medicines and is responsible for its international trademark portfolio.

Emily's litigation experience includes:

The City of New York v. Tavern on the Green, L.P. (Tavern on the Green®): Represented debtors in dispute regarding ownership of the name of the iconic restaurant in Central Park, Tavern on the Green

Jazz Pharmaceuticals Inc., et al. v. Roxane Laboratories (sodium oxybate/Xyrem®): Defended Roxane in ANDA-related patent litigation involving 15 patents on sodium oxybate solution, method of making, method of treatment, drug-drug interaction, pharmaceutical kit and exclusive computerized distribution system; resulted in settlement

Shire LLC, et al. v. Roxane Laboratories (lisdexamphetamine/Vyvanse®): Defended Roxane in ANDA-related patent litigation involving 18 patents on lisdexamphetamine prodrug, x-ray crystallography, pharmacokinetics, methods of preventing abuse and formulation patents

Impax Laboratories Inc. v. Zydus Pharmaceuticals (USA) Inc. (carbidopa and levodopa/Rytary®): Defended Zydus in ANDA-related patent litigation involving a single patent concerning oral formulations indicated for the treatment of Parkinson’s disease; resulted in settlement

Feit Electric Company, Inc. v. Beacon Point Capital, LLC: Represented light bulb manufacturer Feit Electric in declaratory judgment action involving a variety of electrical circuit and hardware patents

In re Consolidated Roflumilast Cases (roflumilast/Daliresp®): Defended Zydus in ANDA-related patent litigation involving three patents concerning oral dosage forms of pure roflumilast for treatment of COPD; resulted in settlement

Astellas Pharma Inc. v. Actavis, et al. (mirabegron/Myrbetriq®): Defended Zydus in ANDA-related patent litigation involving four patents concerning extended release tablets for the treatment of overactive bladder; resulted in settlement

Amgen Inc. v. Sandoz, et al. (apremilast/Otezla®): Defended Zydus in ANDA-related patent litigation involving numerous patents concerning oral pharmaceutical compositions and x-ray powder diffraction peaks of stereomerically pure apremilast for the treatment of psoriasis; trial held

Astellas Pharma Inc. v . Sandoz, et al. (mirabegron/Myrbetriq^®): Defended Zydus in follow-on ANDA-related patent litigation involving patent claims to extended-release formulation and dissolution; trial held